Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $25.60 Average Price Target from Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been given a consensus rating of “Buy” by the seven brokerages that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $25.60.

A number of equities analysts have issued reports on the company. HC Wainwright assumed coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They set a “buy” rating and a $34.00 target price for the company. Wedbush assumed coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 target price for the company.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $15.25 on Friday. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $19.19. The business’s fifty day simple moving average is $13.69.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.39).

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC bought a new position in Maze Therapeutics during the second quarter worth about $28,000. Goldman Sachs Group Inc. bought a new stake in shares of Maze Therapeutics during the first quarter worth approximately $145,000. Rhumbline Advisers acquired a new stake in shares of Maze Therapeutics in the first quarter valued at approximately $80,000. Woodline Partners LP bought a new stake in shares of Maze Therapeutics in the first quarter valued at approximately $10,229,000. Finally, Octagon Capital Advisors LP bought a new stake in shares of Maze Therapeutics in the first quarter valued at approximately $5,153,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.